Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Jetstar to Charge for Overhead Cabin Bags From February 
Apple Restores Telegram to App Store After Content Policy Violation 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
Telegram Restored on Apple App Store After Temporary Removal 
NEW YORK, March 26, 2018 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be participating in the following investor conference:
- Needham Healthcare Conference at 12:45 p.m. ET on Wednesday, March 28, 2018
Webcast information for this event will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.
CONTACT: For more information about
Intercept Pharmaceuticals, please contact:
Intercept Pharmaceuticals:
Mark Vignola
+1-646-747-1000
[email protected]
Media inquiries: [email protected]
Investor inquiries: [email protected]
